Navigating Double Patenting in the USPTO Era of Rulemaking
Navigating Double Patenting in the USPTO Era of Rulemaking
In today’s evolving patent landscape, understanding obviousness-type double patenting (ODP) is critical to securing and maintaining strong intellectual property rights. The Federal Circuit’s evolving case law in the URAA era from Gilead to Novartis, and most recently Cellect and Allergan has significant implications for patent protection strategies.
Join our speakers in this CLE webcast as they explore the latest developments in double patenting jurisprudence and share strategic insights to mitigate risks and optimize patent prosecution. The discussion will cover proactive measures such as removing unnecessary terminal disclaimers before issuance, leveraging patent term extension (PTE), and addressing the risk of ODP to patent term adjustment (PTA). It will also highlight key prosecution strategies, IP portfolio audits to identify potential ODP challenges, and the use of reissue applications to correct PTA-related vulnerabilities.
